PanTher Therapeutics

Board of Directors

Dan Wildman

Dan Wildman is a Strategic Advisor to PanTher Therapeutics. A seasoned executive with more than 35 years of experience in the MedTech industry, Dan is President & Chief Executive Officer of Wildman Ventures, LLC. He also currently serves as a member of the Board of Directors or as a Strategic Adviser for several early-stage organizations.

Prior to joining PanTher Therapeutics, Dan led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide President of Depuy Synthes Spine, the second-largest spine surgery business in the world. Previously, he served as Worldwide President of Ethicon Biosurgery, a division of Ethicon, Inc. While at Ethicon Biosurgery, he led the development and commercialization of a novel combination product based on a biomaterial and biologic formulation. The biosurgery business at Ethicon now exceeds $1.7B in revenue and continues to be one of the fastest-growing companies in J&J’s medical device portfolio.

As a strategic advisor to PanTher, Dan applies this expertise and his decades of experience to advancing the clinical development program for PTM-101 and selecting and prioritizing other Sagittari™ platform product candidates.

Dan holds a BA in Economics from St. Lawrence University.

Maria Palasis, PhD

Manish Bhandari, MD, E-MBA

Darshana Zaveri

Laura Indolfi, PhD

Laura Indolfi, PhD is the Chief Executive Officer and Co-Founder of PanTher Therapeutics. Laura combines science and business knowledge to drive PanTher’s vision. Prior to founding PanTher Therapeutics, she was a postdoctoral associate at the Harvard-MIT Institute for Medical Engineering and Science and served as an entrepreneur-in-residence at the Massachusetts General Hospital Cancer Center.

Laura’s broad professional experience and interests range from biomedical engineering to entrepreneurship and outreach initiatives to promoting science. Her scientific expertise covers multiple therapeutic areas (cardio, cancer, inflammation, regenerative medicine) and approaches (drug delivery, cell therapy, implanted devices). Together with her strong technical background, Laura has hands-on business and managerial know-how developed during her biomedical business training at Sloan and Harvard Business Schools and with several consulting firms.

She was named a TED Fellow, one of 21 people chosen annually by the TED organization who are considered the most disruptive and transformative change-makers in the world. Laura has also attended the prestigious conference “Fortune: Most Powerful Women – Next Gen”, an invite-only summit hosted by Fortune gathering a stellar group of game-changing entrepreneurs, executives, and innovators in business. Laura is also one of the five women selected by Massachusetts Life Science Center and Takeda for their inaugural class in 2018 of the MassNextGen program, honoring exceptional leaders in the biotech industry.

Laura holds a PhD in Biomaterials and MS and BS degrees in Materials Science and Engineering from the University of Naples Federico II in Italy.